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Abstract
Background: 18F-FDOPA positron emission tomography/
computed tomography (PET/CT) is a sensitive nuclear imag-
ing technology for the diagnosis of pheochromocytomas 
(PHEO). However, its utility in determining predictive factors 
for the secretion of catecholamines remains poorly studied. 
Methods: Thirty-nine histologically confirmed PHEO were 
included in this retrospective single-center study. Patients 
underwent 18F-FDOPA PET/CT before surgery, with an evalu-
ation of several uptake parameters (standardized uptake val-
ues [SUVmax and SUVmean] and the metabolic burden [MB] 
calculated as follows: MB = SUVmean × tumor volume) and 
measurement of plasma and/or urinary metanephrine (MN), 
normetanephrine (NM), and chromogranin A. Thirty-five pa-
tients were screened for germline mutations in the RET, 
SDHx, and VHL genes. Once resected, primary cultures of 
5 PHEO were used for real-time measurement of catechol-
amine release by carbon fiber amperometry. Results: The 
MB of the PHEO positively correlated with 24-h urinary excre-
tion of NM (r = 0.64, p < 0.0001), MN (r = 0.49, p = 0.002), com-
bined MN and NM (r = 0.75, p < 0.0001), and eventually plas-
ma free levels of NM (r = 0.55, p = 0.006). In the mutated pa-
tients (3 SDHD, 2 SDHB, 3 NF1, 1 VHL, and 3 RET), a similar 
correlation was observed between MB and 24-h urinary 
combined MN and NM (r = 0.86, p = 0.0012). For the first time, 
we demonstrate a positive correlation between the PHEO-
to-liver SUVmax ratio and the mean number of secretory gran-
ule fusion events of the corresponding PHEO cells revealed 
by amperometric spikes (p = 0.01). Conclusion: While the 
18F-FDOPA PET/CT MB of PHEO strongly correlates with the 
concentration of MN, amperometric recordings suggest that 
18F-FDOPA uptake could be enhanced by overactivity of cat-
echolamine exocytosis. © 2018 S. Karger AG, Basel
S. Moog and S. Houy contributed equally as co-first authors, and S. 
Gasman and T. Cuny as co-last authors, to this work.
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Introduction
Pheochromocytomas (PHEO) define tumors arising 
from secreting adrenomedullary chromaffin cells that 
commonly produce one or more catecholamines whose 
degradation results in the release of metanephrine (MN) 
and normetanephrine (NM) in plasma. Hypersecretion 
of catecholamines can cause sustained or paroxysmal el-
evations in blood pressure, headaches, episodic profuse 
sweating, and palpitations and can ultimately be the cause 
of severe cardiovascular morbidity [1, 2]. Currently, near-
ly 40% of PHEO encountered in the clinic can be associ-
ated with a syndrome of predisposition in which the tu-
mors are likely recurrent, numerous, and/or metastatic 
[3–5].
Besides hormonal evaluation, radiological and nuclear 
medical imaging procedures are required for the diagno-
sis of PHEO, including the search for metastasis. 18F-
FDOPA positron emission tomography/computed to-
mography (18F-FDOPA PET/CT) has both high sensitiv-
ity and high specificity for the characterization of these 
tumors, especially in cases of small hereditary PHEO [6, 
7]. The principle of 18F-FDOPA PET/CT is based on the 
property of neuroendocrine tumor cells to take up L-DO-
PA via the neutral amino acid transporter system L (LAT1 
or LAT2), to decarboxylate it into dopamine thanks to 
amino acid decarboxylase, and to eventually store amino 
acids (such as DOPA) and their biogenic amines in vesi-
cles [8]. A recent study suggests a positive correlation be-
tween the intensity of 18F-FDOPA uptake in patients with 
PHEO and their respective level of urinary MN [9]. How-
ever, the relation between the 18F-FDOPA PET/CT up-
take parameters and the cellular pattern of catecholamine 
secretion in the corresponding tumors may need further 
clarification and new insights. A suitable technique for 
investigating this issue is carbon fiber amperometry, al-
lowing the real-time measurement of catecholamine se-
cretion at the level of a single cell [10].
Further information focusing on the potential correla-
tion between 18F-FDOPA uptake and tumor cell secretion 
could be of a great interest to optimize both medical and 
surgical approaches to treatment of these potentially life-
threatening tumors.
The aim of our study was therefore (1) to evaluate the 
relation between 18F-FDOPA PET/CT uptake and the se-
cretion of catecholamines in patients with histologically 
confirmed PHEO and (2) to compare, in a subgroup of 
PHEO cases, the characteristics of 18F-FDOPA PET/CT 
uptake with the profiles of tumor cell secretion recorded 
in vitro by carbon fiber amperometry.
Subjects and Methods
Patient Population
This retrospective single-center study enrolled 39 patients with 
histologically confirmed PHEO operated between January 2012 
and June 2017 at the Department of Endocrine Surgery. Patients 
with parasympathetic paragangliomas were excluded from the 
study, because they usually do not produce catecholamines. None 
of the patients had a metastatic PHEO at the time of the study.
All patients underwent 18F-FDOPA PET/CT at the time of ini-
tial diagnosis and a complete endocrinological evaluation before 
surgery, including measurement of plasma free MN and NM 
(nmol/L) and/or urinary MN and NM (nmol/24 h) by high-per-
formance liquid chromatography. Chromogranin A (CGA) levels 
were assessed by radioimmunoassay (CgA-RIA CT; CIS Bio Inter-
national, Gif-sur-Yvette, France). The upper limits of normal 
(ULN) of free MN and NM were 4.05 and 9.8 nmol/L in plasma 
and 1,625 and 2,620 nmol/24 h in urine, respectively. The upper 
reference limit for CGA was 100 mg/L. For the sake of consistency, 
we present the plasma free MN and NM as well as the urinary MN 
and NM and the CGA measurements as ratios normalized by the 
ULN. MN and NM ratios in plasma and urine were used to deter-
mine the catecholamine secretion phenotype of the PHEO, as pre-
viously described by Eisenhofer et al. [11]: in the adrenergic phe-
notype, the MN content exceeds 10% of the combined MN and 
NM content, while in the noradrenergic phenotype, the tumors 
present an increase in MN content which remains below 10% of 
the combined MN and NM content. A subset of the tumors was 
defined as poorly secreting if the urinary MN and NM levels were 
below 2 ULN.
When available, genetic assessments for germline mutations in 
SDHB/D, VHL, and RET were made. Histopathological evaluation 
was ultimately considered as the gold standard for the diagnosis of 
PHEO, and it included the tumor size, the proliferation index as-
sessed by Ki-67 labeling (using the MIB-1 antibody), and the PASS 
(Pheochromocytoma of the Adrenal Gland Scaled Score) system 
as previously described by Thompson [12].
18F-FDOPA PET/CT Acquisition Protocol
Images were obtained using a Biograph 6 true point PET/CT 
scanner (Siemens Medical Solutions, Knoxville, TN, USA). Image 
acquisition was started 66 ± 14 min after the direct intravenous 
injection of 300 ± 80 MBq (4 MBq/kg) of 18F-FDOPA. Neither was 
carbidopa used for pretreatment nor was fasting required before 
image acquisition.
The heterogeneity of a lesion was defined during the CT scan 
procedure by the presence of hemorrhagic and/or necrotic tissue.
Image Analysis and Quantification of 18F-FDOPA Uptake
Quantitative parameters of 18F-FDOPA uptake were obtained 
using IntelliSpace Portal 6.4 ISP (Philipps), and they included the 
different standardized uptake values (SUV; i.e., SUVmax, SUVmean, 
lesion-to-liver SUVmax, and lesion-to-liver SUVmean). All 18F-
FDOPA PET/CT scans were interpreted by the same physician. All 
of these values were obtained from the volume of PHEO, which 
was encompassed by an axial slice-by-slice approach. The SUV is 
the ratio between the image-derived radioactivity concentration 
and the whole-body concentration of the injected radioactivity; it 
was calculated as follows: SUV = radioactivity concentration in a 
region of interest (kBq/mL)/(patient weight [g]/injected dose 
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[kBq]). The highest SUV in all the tumor volume was defined as 
the SUVmax, whereas the average of the SUV was defined as the 
SUVmean. A normal liver region was defined by drawing a region 
of interest to derive tumor-to-background ratios (PHEO-to-liver 
SUV) in order to facilitate comparisons between patients.
The metabolic burden (MB) was determined to serve as an im-
age-derived index of overall tumor activity per patient, as previ-
ously described [13], and was calculated for each adrenal lesion as 
follows: MB = SUVmean × tumor volume. If the patient had bilat-
eral PHEO, the whole-body MB was calculated as the sum of the 
MB of each lesion.
Primary Culture of Human PHEO
After resection, the PHEO was cut longitudinally in two parts, 
and a piece of the tumor zone was dissected and placed in the op-
erating room in CMF HBSS (Hank’s Balanced Salt Solution with-
out Ca2+ and Mg2+: 0.3 mM Na2HPO4, 4.1 mM NaHCO3, 0.4 mM 
KH2PO4, 138 mM NaCl, 5.3 mM KCl, 5.5 mM glucose, 1.2 mM 
CaCl2, 0.5 mM MgCl2, and 0.4 mM MgSO4) supplemented with 
0.2% FBS (fetal bovine serum) and 1% penicillin/streptomycin. 
The tumor was cut into small pieces (1 mm3) before centrifugation 
at 250 g for 5 min in complete RPMI (RPMI, 15% FBS, and 1% 
penicillin/streptomycin).
A pellet was resuspended in complete RPMI and settled during 
15–30 min at room temperature in order to eliminate blood cells 
and fat with the supernatant. This step was repeated twice. The 
tumor pieces were washed in CMF HBSS, centrifugated at 250 g 
for 5 min, then dissociated with 1.5 mg/mL of collagenase B 
(Roche) with 1 mg/mL of dispase II (Gibco) in HBSS during 45 
min at 37  ° C under moderate agitation. After sedimentation, the 
supernatant was recovered (fraction 1) and the pellet crushed in 
CMF HBSS. After renewed sedimentation, the supernatant was 
recovered again (fraction 2). Both fractions were centrifugated for 
5 min at 800 g at room temperature and resuspended into 3 mL of 
complete RPMI. Three hundred microliters of suspended cells 
were plated on polylysine-coated cover glass (MatTek). The cells 
were then incubated at 37  ° C in a water-saturated atmosphere with 
5% CO2, and complete RPMI was added the following day.
Carbon Fiber Amperometry
Only patients with sporadic PHEO and homogeneous lesions 
on the CT scan were included. Two days after culture, chromaffin 
cells originating from PHEO were washed with Locke’s solution 
(140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 
mM MgSO4, 0.01 mM EDTA, 15 mM HEPES, and 11 mM glucose; 
pH 7.5) and processed for catecholamine release measurements by 
amperometry as previously described [14].
Briefly, a carbon fiber electrode of 5 μm diameter (ALA Scien-
tific Instruments) was held at a potential of +650 mV compared 
with the reference electrode (Ag/AgCl) and approached close to 
the cells. Secretion of catecholamines was induced by a 10-s pres-
sure ejection of 100 mM potassium (K+) solution from a micropi-
pette positioned 10 μm from the cell and recorded over 60 s. The 
amperometric recordings were performed with an AMU130 am-
plifier (Radiometer Analytical), calibrated at 5 kHz, and digitally 
low-pass filtered at 1 kHz.
An analysis of the amperometric recordings was performed as 
previously described with a macro (laboratory of Dr. R. Borges; 
http://webpages.ull.es/users/rborges/) written for Igor software 
(WaveMetrics), allowing automatic spike detection and extraction 
of spike parameters [15]. The spike parameter analysis was re-
stricted to spikes with amplitudes higher than 5 pA. The number 
of amperometric spikes was counted as the total number of spikes 
with an amplitude greater than 5 pA within 60 s. We investigated 
the total number of spikes per cell corresponding to the number of 
exocytotic events, the quantal size of individual spikes (Q) corre-
sponding to the spike area above the baseline, which is propor-
tional to the amount of amines per granule, and the spike ampli-
tude (Imax), which corresponds to the maximal flow of catechol-
amines released per granule.
Statistical Analysis
For statistical analysis, GraphPad Prism® 7.0 (GraphPad Soft-
ware, San Diego, CA, USA) was used. The data are reported as 
Table 1. Clinical, biochemical, and functional characteristics of the 
39 patients with PHEO
Clinical characteristics (n = 39)
Age, years 53±15
Female 22 (56%)
Presentation
Incidentaloma 13 (22%)
Hypertension 24 (60%)
Symptoms related to abdominal mass 11 (27%)
Paraclinical characteristics (n = 39)
Germline mutations 12/35
RET 3
VHL 1
NF1 3
SDHB 2
SDHD 3
Biochemical analysis
Adrenergic/noradrenergic phenotype 26/13
Total urinary MN and NM, ULN ratio (n = 34) 6.3±6.6
Urinary MN, ULN ratio (n = 37) 7.5±11.7
Urinary NM, ULN ratio (n = 37) 6.8±6.8
Plasma free MN, ULN ratio (n = 22) 5.5±8.1
Plasma free NM, ULN ratio (n = 23) 5.6±6.1
CGA, mg/L (n = 30) 345±443
18F-FDOPA PET/CT uptake parameters
SUVmean 8.9±5.0
SUVmax 10.4±6.1
Metabolic burden, cm3 260±375
Histology
Size, cm 4.5±2.6
Bilateral tumor 2 (5%)
Metastatic tumor 0 (0%)
PASS 1 (0–4)
Ki-67 index 2 (0–6)
Values are presented as means ± SD/(range) or n (%). PHEO, 
pheochromocytoma; VHL, von Hippel-Lindau tumor suppressor; 
NF1, neurofibromatosis type 1; SDHx, succinate dehydrogenase; 
MN, metanephrine; NM, normetanephrine; CGA, chromogranin 
A; ULN, upper limit of normal; SUV, standardized uptake value; 
PASS, Pheochromocytoma of the Adrenal Gland Scaled Score.
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means ± SD or SEM. Comparative statistical evaluations between 
groups (biological phenotype clusters or genotype clusters) were 
accomplished with a Mann-Whitney test followed by Tukey’s test 
for multiple post hoc comparisons. For correlations between pa-
rameters of 18F-FDOPA uptake and biological measurements or 
amperometric experiments, Spearman’s rank order was per-
formed. A p value < 0.05 was considered to be significant for all 
tests.
Results
Overall Patient Characteristics
This study included 39 patients (17 males and 22 fe-
males; mean age 53 ± 15 years) who had 41 histologically 
proven PHEO (2 patients had bilateral tumors). Hyper-
tension was found in 24 patients (60%) at the time of di-
agnosis. Incidentaloma was the mode of presentation in 
13 patients (22%), a proportion higher than the 5% re-
ported in the literature [16]. Biochemically, an adrenergic 
secretion phenotype, according to Eisenhofer’s criteria, 
was found in 26 patients (65%) who presented a mean 
urinary MN level 11-fold above the ULN. The remaining 
thirteen patients had a biochemical phenotype in line 
with an oversecretion of norepinephrine, as their mean 
level of urinary NM was 6-fold upper the normal limit 
value (Table 1). In total, 6 patients (15%) were considered 
as having poorly secreting tumors.
A total of 35 patients were screened for germline mu-
tations, and amongst them, 12 (34%) carried mutations 
as follows: SDHD (n = 3), SDHB (n = 2), NF1 (n = 3), VHL 
(n = 1), and RET (n = 3). Half of them had already been 
surgically treated for other contralateral PHEO or para-
sympathetic paragangliomas.
Finally, the median histopathological PASS was 1 
(range 0–4), with a median Ki-67 index of 2 (range 0–6) 
and a mean tumor size of 4.5 ± 2.6 cm (Table 1). While 
there was no statistically significant difference in tumor 
size between the adrenergic and noradrenergic pheno-
typic subgroups, the PHEO were of a significantly small-
er size in the 12 patients with germline mutations, includ-
ing the 5 SDHB/D mutations, than in their nonmutated 
counterparts (3.1 ± 2.3 vs. 6.1 ± 2.9 cm, respectively; p = 
0.005).
18F-FDOPA PET/CT and Hormonal Secretion Data
18F-FDOPA PET/CT data were available for all pa-
tients. The mean SUVmax and SUVmean of the lesions were 
10.4 ± 6.1 and 5 ± 3.3, respectively. The mean tumor vol-
ume was 69 ± 101 cm3 and the mean MB was 260 ± 375 
cm3. Evaluating the usefulness of 18F-FDOPA PET/CT in 
the determination of catecholamine secretion, we found 
a statistically significant positive correlation between the 
tumor MB and the corresponding level of 24-h urinary 
NM (r = 0.64, p < 0.0001, n = 36; Fig. 1a), MN (r = 0.49, 
p = 0.002, n = 35; Fig. 1b), and combined MN and NM 
(r = 0.75, p < 0,0001, n = 33; Fig. 1c). Similarly, a positive 
correlation was observed between the tumor MB and the 
concentrations of plasma free NM (r = 0.55, p = 0.006, 
n = 23; Fig. 1d) and CGA (r = 0.61, p = 0.0005, n = 28; 
Fig. 1e) but not with plasma MN (r = 0.11, p = 0.6, n = 22; 
data not shown).
In contrast, there was no correlation between the SUV 
characteristics of the PHEO (SUVmean or SUVmax) and the 
corresponding concentrations of MN or NM either in 
plasma or in the 24-h urinary sample (data not shown), 
except for the plasma levels of CGA, for which a positive 
correlation was observed with both the SUVmean and the 
SUVmax of the PHEO (r = 0.41, p = 0.02, and r = 0.55, p = 
0.0019, respectively; data not shown).
In addition, the 6 poorly secreting PHEO showed a 
trend for both a lower MB (p = 0.06) and a lower size of 
the tumors (3.35 ± 1.2 cm vs. 5.1 ± 0.4 cm; p = 0.07) com-
pared to the secreting PHEO. A significantly lower MB 
was observed in the 12 mutated PHEO as compared to the 
sporadic PHEO (87 ± 109 vs. 385 ± 494 cm3; p = 0.008), 
mainly due to the fact that the mutated PHEO had a 
smaller size than the nonmutated tumors (see earlier). Of 
note, the MB of the mutated PHEO, even when they were 
smaller, positively correlated with urinary levels of MN 
(r = 0.69, p = 0.01, n = 11; data not shown), NM (r = 0.64, 
p = 0.03, n = 11; data not shown), and combined MN and 
NM (r = 0.86, p = 0.0012, n = 10; Fig. 1f). In the subgroup 
of PHEO with SDHB and SDHD mutations (MB 24 ± 23 
cm3), we did not find any correlation with urinary levels 
of catecholamines (r = 0.4, p = 0.75; data not shown).
At the histopathological level, the PASS and/or the Ki-
67 proliferation index of the tumor did not correlate one 
way or another with its corresponding 18F-FDOPA PET/
CT uptake parameters (data not shown).
In summary, we found a positive correlation between 
the MB of the PHEO as calculated by 18F-FDOPA PET/
CT and their respective circulating (plasma) or excreted 
(urinary) levels of MN and/or NM. We then wondered if, 
besides the concentration of MN, the pattern of catechol-
amine secretion as measured by amperometry could also 
influence the 18F-FDOPA PET/CT uptake by the tumor.
Amperometry Analysis
Among our samples, 5 freshly resected PHEO origi-
nating from 5 distinct patients (2 women and 3 men; all 
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Fig. 1. Correlation between the 18F-FDOPA PET/CT metabolic burden of the pheochromocytomas and the re-
spective upper limit of normal (ULN) ratios of 24-h urinary normetanephrine (NM) (a), 24-h urinary metaneph-
rine (MN) (b), 24-h urinary combined MN and NM (c), plasma free NM (d), plasma chromogranin A (CGA) 
(e), and 24-h urinary combined MN and NM in the subgroup of mutated pheochromocytomas (n = 11) (f). For 
correlation, Spearman’s rank order was performed.
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PHEO sporadic, 3 of the adrenergic and 2 of the nor-
adrenergic phenotype) were placed in primary culture in 
order to perform real-time single-cell catecholamine se-
cretion measurements using carbon fiber amperometry 
[10]. Tumor chromaffin cells were stimulated with a de-
polarizing concentration of K+ for 10 s and amperometric 
spikes were measured over a period of 60 s. A representa-
tive amperometric trace recorded from a chromaffin cell 
cultured from the PHEO of patient 2 is illustrated in Fig-
ure 2a. Each spike represents a single granule fusion 
event, with the surface area or quantal size (Q) being pro-
portional to the amount of catecholamines released per 
event, and the spike amplitude value (Imax) displaying the 
maximal flux of catecholamines (Fig. 2b). Table 2 sum-
marizes the 18F-FDOPA PET/CT and amperometric pa-
rameters for this subgroup of PHEO.
The mean number of spikes detected per cell was 24.7 ± 
4.4, the mean area under the spike trace (Q) was 0.83 ± 0.12 
pC, and the mean Imax was 16 ± 2.0 pA. No correlation was 
found between either the SUV or the MB of the tumor and 
the corresponding quantal size Q or the spike height value 
Imax (data not shown), meaning that the amount of cate-
cholamine stored per secretory granule does not seem to 
influence the 18F-DOPA uptake of the tumor.
It is noteworthy that we observed for the first time a 
strictly positive correlation between the lesion SUVmax/
liver SUVmax ratio and the number of spikes per cell ob-
tained from the corresponding tumor (r = 1, p = 0.01; 
Fig. 2c), which suggests that the amount of uptake (as re-
flected in the SUVmax) is related to the total number of 
exocytotic events.
Discussion
Nuclear medical imaging modalities play a pivotal role 
in the management of patients with adrenal lesions, espe-
cially PHEO [6]. Over the past years, PET/CT examina-
tions have marked a step forward regarding localization, 
relapse, and assessment of the aggressiveness of the dis-
ease. Recent studies also suggest that PET/CT may, in cer-
tain circumstances, yield information about the function-
al status of an adrenal lesion, especially in case of cortisol-
secreting lesions [17].
In this study, in a series of 39 operated PHEO we found 
a positive correlation between 18F-FDOPA MB and the 
corresponding urinary and/or plasma concentrations of 
MN and NM. While only a few studies have been pub-
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Fig. 2. a Amperometric recording of cate-
cholamine release after stimulation of one 
chromaffin cell. b Schematic representa-
tion of one amperometric spike. Each spike 
represents a single granule fusion event, 
with the surface area or quantal size (Q) 
being proportional to the amount of cate-
cholamine released per event, and the spike 
height value (Imax) displaying the maximal 
flux of catecholamines. c Correlation be-
tween the mean number of spikes recorded 
by amperometry in primary culture of 5 
pheochromocytomas (PHEO) and their 
corresponding lesion-to-liver maximum 
standardized uptake value (SUVmax) ratio. 
For correlation, Spearman’s rank order was 
performed.
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lished on the topic, some similar observations have been 
made by others in the past [9, 18, 19]. However, there is 
still no consensus concerning the best predictive 18F-
FDOPA PET/CT uptake parameter to be used in clinical 
practice. Like ours, the recent study published by Amo-
dru et al. [9] was a retrospective and single-center trial. In 
their study, 56 patients with a median age of 47.5 years 
were included. There were fewer patients with a genetic 
mutational background (n = 11; 19.6%), including 5 RET, 
2 SDHB, 2 SDHD, 1 NF1, and 1 VHL mutation. The up-
take parameters assessed during the 18F-FDOPA exami-
nation included tumor SUVmax, tumor SUVmean, MTV 
42% (defined by the region enclosed by a 42% isocontour 
around the maximal PET voxel), and total lesion uptake, 
which corresponded to tumor SUVmean × MTV 42%. 
In that study, the tumor SUVmax, SUVmean, and tumor 
SUVmax-to-liver SUVmax ratio showed a statistically sig-
nificant correlation with urinary MN levels. Interestingly, 
significant positive correlations were observed between 
the value of urinary MN and MTV 42% and total lesion 
uptake, respectively, a result close to the one observed in 
our study with the MB.
The study by Amodru et al. [9] showed that the 
SUVmax of PHEO correlates with the concentration of cir-
culating catecholamines, whereas Imani et al. [19] did not 
find any statistically significant correlation between the 
SUVmax of PHEO and the corresponding biochemical 
markers. This discrepancy could be due to the SUVmax 
parameter itself, which is subject to many sources of vari-
ability that are not controlled or even taken into account 
in most reported studies and which reflects a single-pixel 
value [20, 21]. The synthesis of catecholamines and their 
subsequent secretion in PHEO, albeit heterogeneous, are 
likely to occur in all parts of the tumor, so that whether 
the SUVmax is a reliable tool for predicting the capacity of 
the tumor to secrete catecholamines is questionable. Un-
til now, the SUVmax has mostly been used to predict the 
malignancy or proliferative activity [17, 22, 23] rather 
than the secretion status of different types of tumors – in-
cluding adrenal cortical tumors, in which it strongly cor-
relates with the definitive histopathological Weiss score 
system [24].
Our study shows that the MB of PHEO, which takes 
into consideration both the mean of the SUV and the vol-
ume of the lesion, estimates the concentration of circulat-
ing catecholamines, since the “real” measurement of cat-
echolamine secretion by the tumor would require a so-
phisticated approach including tumor sampling. Two 
other previous studies also identified a positive correla-
tion between biochemical parameters of medullary thy-
roid carcinoma and carcinoid tumor and the whole MB 
of the tumor as calculated during 18F-FDOPA PET/CT 
[25, 26].
Using the MB as a predictor of catecholamine concen-
tration is subject to the fact that the size of a PHEO posi-
tively correlates with the concentration of NM and MN, 
as suggested in a previous study [27]. As such, a trend for 
a lower MB was observed in our subgroup of poorly se-
creting PHEO (defined by an intermediate secretion sta-
tus below 2 ULN) compared to their secreting counter-
parts. While conducting this study, we wondered if simi-
lar concentrations of MN and NM would be observed in 
a PHEO alternatively secreting high amounts of catechol-
amines followed by periods of quiescence (i.e., paroxys-
mal secretion) and in a PHEO which would permanently 
release moderate levels of catecholamines. While, bio-
chemically, it could lead to similar concentrations, a 
strong difference remains in terms of the pattern of secre-
tion, and whether the uptake of 18F-FDOPA could be in-
fluenced by this pattern of secretion is currently un-
known. This hypothesis prompted us to compare, in the 
second part of this work, the 18F-FDOPA uptake param-
Table 2. Clinical, functional, and amperometric characteristics of 5 primary cultures of human pheochromocytomas
Patient 
No.
Sex Tumor size, 
mm
Secretion 
phenotype
Lesion SUVmax/
liver SUVmax
Metabolic 
burden, cm3
Number of cells 
analyzed by 
amperometry
Mean number 
of spikes per 
cell ± SEM
Mean 
charge Q ± 
SEM, pC
Mean amplitude 
Imax ± SEM, pA
1 F 80 AD 7.2 650 14 18.4±4.5 1.27±0.10 13.7±0.80
2 M 37 AD 12 84 19 32±6.6 0.90±0.10 21.3±2.16
3 F 50 AD 9.3 220 23 18.6±2.2 0.68±0.05 11.3±0.81
4 M 44 NAD 6.7 378 21 16.3±2.0 0.81±0.10 20.2±2.71
5 M 40 NAD 13.2 278 6 38.5±8.5 0.51±0.12 13.7±2.90
Mean ± SEM 50±7.7 9.6±1.3 322±94 16.6±3.0 24.7±4.4 0.83±0.12 16±2.0
SUV, standardized uptake value; AD, adrenergic phenotype; NAD, noradrenergic phenotype.
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eters of 5 PHEO with their respective capacity of secretion 
reflected in the number of exocytotic events obtained af-
ter stimulation by amperometric recordings. To the best 
of our knowledge, we here show for the first time in a 
translational approach that a positive correlation exists 
between the PHEO-to-liver SUVmax ratio and the mean 
number of spikes per cell recorded during carbon fiber 
amperometry. Our results thus suggest that the more im-
portant exocytic activity the PHEO has, the more uptake 
of 18F-FDOPA occurs, leading to high SUVmax values.
In contrast, no correlation was observed between any 
of the amperometric parameters of a PHEO and its MB, 
and several hypotheses may subsequently be discussed. 
For instance, the MB reflects the metabolic activity of the 
lesion in its entirety, which means that the result obtained 
is the synthesis of poorly as well as highly secreting PHEO 
cells. However, amperometric experiments are conduct-
ed on a single cell, being either a poorly, an intermedi-
ately, or a highly secreting cell. This could also be the rea-
son why a positive correlation is rather observed with the 
SUVmax of a PHEO, since this parameter assesses a high-
ly active zone of the tumor where cells take up consider-
able amounts of 18F-FDOPA and, therefore, are likely all 
to be highly secreting. Following this point, it is therefore 
not surprising to observe that the MB, which represents 
the whole uptake of a PHEO at the metabolic imaging 
level, positively correlates with the level of urinary/plas-
matic catecholamines, which reflect the secretionary ac-
tivity of the entire PHEO at the biological level.
An unresolved question that was raised with the am-
perometric results of our study is the peculiar aspect of 
head and neck paragangliomas, which are tumors with 
usually high uptake of 18F-FDOPA but normal concen-
trations of plasma MN. Most of human paragangliomas, 
whatever their primary location, express high levels of 
LAT, the neutral amino acid transporter system L in-
volved in the uptake of DOPA [28], which may explain 
their propensity to take up high levels of the radiotracer. 
However, as compared to PHEO, paragangliomas have a 
lower expression of the genes involved in catecholamine 
synthesis (i.e., tyrosine hydroxylase and/or phenyletha-
nolamine N-methyltransferase) [29, 30]. As such, a hy-
pothesis could be that certain paragangliomas have the 
molecular equipment required for DOPA uptake, albeit 
without the capacity to insure catecholamine production 
and secretion. In order to clarify these questions, ampero-
metric experiments will have to be conducted on para-
gangliomas.
Finally, our study has obvious inherent limitations due 
to its retrospective nature. In this respect, we only includ-
ed patients with well-characterized biological data and 
complete 18F-FDOPA PET/CT reports. Because we in-
cluded surgically treated patients, meaning that a major-
ity of these patients should have been diagnosed with 
symptoms of catecholamine hypersecretion, correlations 
might be slightly overestimated. However, an unexpect-
edly high prevalence of incidental PHEO was noted in our 
series – at least higher than the one reported in the litera-
ture. Also, over the study period, 18F-FDOPA PET/CT 
acquisition has not been performed according to a strict 
protocol, as is the case in prospective studies, and could 
therefore be the source of reproducibility bias. To avoid 
excessive variability between the data, all of our 18F-FDO-
PA PET/CT scans were interpreted by the same physi-
cian. Finally, there were only a small number of mutated 
PHEO and a limited representation of specific mutations 
due to their relative rarity in our series, which also con-
stitutes a limitation of this study. As such, only sporadic 
PHEO were used in the amperometric analysis, because 
mutated PHEO do not have the same pattern of 18F-FDO-
PA uptake [7]. Nevertheless, other experiments will have 
to be performed on this subgroup of patients to confirm 
or disprove these data.
In conclusion, PHEO are life-threatening tumors 
which are the source of significant morbidity in clinical 
practice [31]. Rather than assessing the total amount of 
catecholamines, it appears critical to improve our under-
standing of the mechanisms involved in the pattern of 
secretion displayed by these tumors, as PHEO-induced 
mortality mainly occurs during an adrenergic storm, 
when the tumors suddenly release considerable amounts 
of catecholamines [32]. While the MB as provided by 18F-
FDOPA PET/CT correlates with the concentration of cat-
echolamines, further investigation is needed to specify 
whether the SUVmax may serve as a reliable tool to predict 
the secretion pattern of the tumor, as suggested by am-
perometric experiments.
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